Altaminn Capsule 150 milligrams (D-Penicillamine)

Adult dose

1. Wilson's disease ○Adults: Administer 1g of D-penicillamine per day orally in 4 divided doses (30 minutes before meals or 3 hours after the evening meal). 2. Lead or mercury poisoning ○Adults: Administer 250mg of D-penicillamine per dose orally 3-4 times daily (30 minutes before meals or 3 hours after the evening meal). 3. Cystinuria, cystine stones ○Adults: Administer 1-4g of D-penicillamine per day in 4 divided doses (30 minutes before meals or 3 hours after the evening meal). Start with an initial dose of 250mg per day and gradually increase to the required dose. 4. Rheumatoid arthritis, chronic active hepatitis, scleroderma Weeks 1-4: Administer 150mg per dose orally once daily (maximum 250mg per day). Weeks 5-8: Administer 250mg per dose orally once daily (maximum 450mg per day). Weeks 9-12: Administer 150mg per dose orally twice daily (maximum 600mg per day). Week 13 onward: Increase the daily dose by 50-150mg at intervals of 4-12 weeks, up to 750mg per day. Depending on symptoms, the dose may be increased to 1g per day. When clinical improvement is evident, gradually reduce the dose by 50-150mg to maintain the minimum effective dose. The usual maintenance dose is 300-450mg per day. Discontinue this drug if symptoms do not improve.

Child dose

1. Wilson's disease ○Children: Gradually increase the dose to 20mg per kg of body weight per day, divide it into doses, and administer before meals. 2. Lead or mercury poisoning ○Children: Administer 20-30mg per kg of body weight per day in several divided doses. 3. Cystinuria, cystine stones ○Children: Administer 30mg per kg of body weight per day in 3-4 divided doses. 5. Juvenile rheumatoid arthritis Start treatment at a dose of 5-10mg per kg of body weight per day. Gradually increase the dose to 15-20mg per kg of body weight per day. When clinical improvement is evident, reduce the dose to the maintenance dose of 10-15mg per kg of body weight.

This medication should be used with special caution as serious blood disorders may occur. It should not be administered to specific patient groups, such as those taking gold preparations, patients with a history of blood disorders or kidney disorders, patients with systemic lupus erythematosus, and children in growth periods. Additionally, women who are pregnant or breastfeeding, elderly patients, patients right after surgery, and patients with decreased bone marrow function should only be administered if absolutely necessary and under careful consideration. This medication may cause various adverse reactions, including decreased blood cells, pneumonia, renal dysfunction, skin rash, and liver dysfunction; if symptoms occur, cease use immediately and consult medical personnel. Regular blood tests, kidney function tests, and liver function tests should be carried out before and during administration to early detect abnormal signs and respond appropriately. Interactions may occur when combined with other medications, so especially when used with gold preparations, immunosuppressants, iron preparations, antacids, zinc preparations, it is essential to inform medical personnel. Use during pregnancy or breastfeeding is not advised, and if unavoidable, a careful decision should be made after consultation with a specialist. Safety has not been fully established for use in children or the elderly, hence it should only be used in special cases under medical guidance.

• Thrombocytopenia
• leukopenia
• anemia
• nephrotic syndrome
• pancytopenia
• aplastic anemia
• neutropenia
• agranulocytosis
• monocytosis
• leukocytosis

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. Storing it this way can help maintain the medication's effectiveness for a longer period.

Appearance

Capsule form containing white powder: yellow-orange for the upper part; milky-white hard capsule for the lower part

Package unit

30 capsules per bottle